BioSpace News Archive

New offering expands Pfizer’s growth hormone portfolio of medicines and treatment options for rare diseases

Talaris Therapeutics, Inc.today announced the initiation of the company’s Phase 2 FREEDOM-2 study.

Alkermes plc (Nasdaq: ALKS) today announced plans to present research from its psychiatry and addiction portfolios at upcoming scientific conferences this fall.

World Psoriasis Day: AxisBiotix-Ps ™ , Food Supplement Targeting Psoriasis Symptoms Launches Today

Oramed Pharmaceuticals Inc. today announced that its majority-owned subsidiary, Oravax Medical Inc. ( www.ora-vax.com ), has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its oral COVID-19 vaccine and preparations to begin the trials are now underway.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data relating to the discovery and optimization of CK-3828136 (CK-136) were presented at the 2021 Medicinal Chemistry Gordon Research Conference in West Dover, VT.

Immutep Limited is pleased to announce it has received positive feedback from the European Medicines Agency (EMA) regarding its clinical development program for lead product candidate, eftilagimod alpha (efti), including the planned Phase III trial in MBC.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021.

Centene Corporation (NYSE: CNC) will host its 2022 Financial Guidance and Investor Meeting on Friday, December 10, 2021

Vaso Corporation announces the amendment of the sales representation agreement between its subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, and GE Healthcare, the healthcare business unit of General Electric Company, originally signed on May 19, 2010.